New MGA Analysis of the Adalimumab Biosimilars Market in the United States

Feb 21, 2023 | Analysis, Press Releases

New MGA Analysis of the Adalimumab Biosimilars Market in the United States Below is the press release from Biosimilars Council regarding the new report from MGA examining biosimilar competition for Humira (adalimumab) in the US market. Washington, D.C. (February 21,...

Humira Rivals Set to Try to Drive Down Cost of Blockbuster Drug

Jan 31, 2023 | Interviews

Humira Rivals Set to Try to Drive Down Cost of Blockbuster Drug Celine Castronuovo | Bloomberg Law News “More than 1.4 million patients have used Humira globally, according to AbbVie. The drug takes up a huge chunk of Medicare spending in the US, with an HHS...

New MGA Analysis of Biosimilar Coverage in Commercial Medical Benefit

Dec 8, 2022 | Analysis

New MGA Analysis of Biosimilar Coverage in Commercial Medical Benefit A new MGA white paper from CEO Alex Brill and Principal Christy Robinson shows a positive outlook for biosimilar coverage in the commercial medical benefit. While patients and physicians play a role...

Updated MGA Report Presents Biosimilar Market Opportunities in Ophthalmology

Jul 14, 2022 | Analysis

Updated MGA Report Presents Biosimilar Market Opportunities in Ophthalmology MGA releases an updated report, “Biosimilar Market Opportunities in Ophthalmology.”  Authored by founder and CEO Alex Brill, the report examines the economics of biologic drugs for...

New MGA Report Presents Biosimilar Market Opportunities in Ophthalmology

May 26, 2022 | Analysis

New MGA Report Presents Biosimilar Market Opportunities in Ophthalmology MGA releases a new report, “Biosimilar Market Opportunities in Ophthalmology.” Authored by founder and CEO Alex Brill, the report examines current trends and economics in the ophthalmology...